Guggenheim Reaffirms “Buy” Rating for ANI Pharmaceuticals (NASDAQ:ANIP)

Guggenheim reaffirmed their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report published on Friday,Benzinga reports. Guggenheim currently has a $86.00 price target on the specialty pharmaceutical company’s stock.

Several other research firms have also commented on ANIP. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 8th. HC Wainwright restated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Stock Up 4.6 %

Shares of ANIP stock opened at $68.12 on Friday. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.00. The stock has a market cap of $1.48 billion, a P/E ratio of -123.85 and a beta of 0.49. The stock has a 50 day moving average of $62.34 and a 200 day moving average of $59.08. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,800 shares of company stock valued at $170,208 over the last quarter. 12.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in shares of ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in ANI Pharmaceuticals by 14.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock valued at $854,000 after buying an additional 1,972 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of ANI Pharmaceuticals by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after acquiring an additional 17,314 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of ANI Pharmaceuticals by 6.1% during the 3rd quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock worth $705,000 after acquiring an additional 691 shares during the period. Finally, Barclays PLC boosted its position in shares of ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after acquiring an additional 135,003 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.